Prognostic Factors for Long-Term Survival in 102 Consecutive Pancreatic Resections for Primary Neuroendocrine Tumor Abstract #1914

Introduction: Neuroendocrine tumors (NET) of the pancreas represent a rare entity of primary pancreatic tumors. However, with the continuous progress in modern diagnostics NET`s are increasingly detected and prognostic factors are being reevaluated to establish personalized treatment concepts.
Aim(s): The aim of this study was to analyze our patient population with regard to surgical outcome and overall survival.
Materials and methods: 102 consecutive patients who underwent pancreatic resection for primary pancreatic NET at our institution were analyzed for surgical outcome and radicality as well as for tumor size, Ki-67 and MIB-1 status.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Dr. med. Fritz Klein
Keywords: NET, pancreas, surgery

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2197 Tumor Necrosis of Primary Malignancy Affects Survival and Outcome in Patients with Liver Metastases from Neuroendocrine Tumors
Introduction: Reliable biomarkers represent a crucial unmet need in the management of neuroendocrine tumors. Tumor necrosis has been suggested to have a prognostic value in selected solid tumors but is not included in established WHO NET Grading Systems. However, little is known regarding the influence of tumor necrosis on tumor progression and prognosis in patients with liver metastasis from neuroendocrine tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Dr. med. Georgi Atanasov
#2207 Circulating Neuroendocrine Gene Transcripts (NETest) Decrease Early after Radical Surgery: Preliminary Results of a Prospective Study
Introduction: Specific biomarkers for predicting response and risk of recurrence after surgery for enteropancreatic neuroendocrine tumours (EP-NETs) are still lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Francesca Muffatti
#1868 Study Protocol: Prospective, Randomized Controlled Trial on the Effect of Primary Resection in Advanced Metastatic NEN of Pancreas and Midgut (PRESNENAS)
Introduction: The role of Primary Tumor resection in advanced metastatic NEN is discussed controversely.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Dr. Nehara Begum
Authors: Begum N, Pavel M, Goretzki P, ...
#2094 Disease Control in Progressive Pancreatic and Intestinal Neuroendocrine Tumors by Combined Treatment with Lanreotide Autogel and Temozolomide: The SONNET Study
Introduction: In advanced NETs antiproliferative treatment options beyond somatostatin analogues remain limited. Temozolomide (TMZ) has shown efficacy in NETs alone or combined with other drugs.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Prof Marianne Pavel
Authors: Pavel M, Denecke T, Lahner H, Hörsch D, ...
#518 CK19 and KIT Immunostaining is a Useful Adjunct to Ki-67-Based Grading of Pancreatic NET: A Study on Matched Cytological and Histological Samples
Introduction: Pancreatic neuroendocrine tumors (NET) are rare neoplasms. Recent evidence suggests that Ki-67 staining predicts their behavior. Even more recently, a prognostic role has been proposed also for CK19 and KIT. This panel might guide patient management. CK19 and KIT have not yet been evaluated on NET on Fine needle aspiration samples (FNAs).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Giancarlo Troncone
Keywords: FNA, pancreas, NET, Ki-67, Kit, CK19